Valuation: XOMA Royalty Corporation

Market Cap 534M 469M 432M 403M 759M 50.82B 775M 5.2B 2.01B 24.94B 2.01B 1.96B 86.81B P/E 2026 *
54.2x
P/E 2027 * -852x
Enterprise Value 534M 469M 432M 403M 759M 50.82B 775M 5.2B 2.01B 24.94B 2.01B 1.96B 86.81B EV / Sales 2026 *
8.8x
EV / Sales 2027 * 10.2x
Free-Float
97.66%
Yield 2026 *
-
Yield 2027 * -
1 day+0.28%
1 week+1.12%
Current month+0.28%
1 month+2.23%
3 months+28.84%
6 months+60.29%
Current year+60.29%
1 week 42.01
Extreme 42.01
42.74
1 month 40.76
Extreme 40.76
42.74
Current year 22.29
Extreme 22.29
42.81
1 year 22.29
Extreme 22.29
42.81
3 years 13.48
Extreme 13.48
42.81
5 years 13.48
Extreme 13.48
42.81
10 years 3.96
Extreme 3.96
46.32
Manager TitleAgeSince
Chief Executive Officer 51 2022-12-31
Director of Finance/CFO 42 2026-01-11
Chief Investment Officer 45 2023-01-02
Director TitleAgeSince
Chairman 70 2024-01-06
Director/Board Member 72 2012-12-12
Director/Board Member 52 2017-02-15
Date Insider Type Main position Quantity % Market Cap.
05-20Free

Director

3,586 0.0296%
05-20Free

Director

3,586 0.0296%
05-20Free

Director

3,586 0.0296%
Change 5-day change 1-year change 3-year change Capi.($)
+0.28%+1.12%+61.81%+125.62% 534M
+1.93%-2.46%+49.37%+67.25% 572M
+1.06%0.00%-4.67%-14.88% 364M
+5.53%+9.87%-30.09%-40.92% 79.33M
-3.85%-9.91%-28.57%+6.95% 50.84M
Average +0.99%-0.19%+9.57%+28.81% 320.21M
Weighted average by Cap. +1.18%-0.66%+34.83%+60.79%

Financials

2026 *2027 *
Net sales 60.73M 53.32M 49.08M 45.74M 86.26M 5.77B 88.01M 590M 229M 2.83B 228M 223M 9.86B 52.5M 46.1M 42.43M 39.54M 74.56M 4.99B 76.08M 510M 198M 2.45B 197M 193M 8.53B
Net income 15.03M 13.2M 12.15M 11.32M 21.35M 1.43B 21.78M 146M 56.62M 702M 56.45M 55.22M 2.44B -900K -790K -727K -678K -1.28M -85.57M -1.3M -8.75M -3.39M -42M -3.38M -3.31M -146M
Net Debt - -
Logo XOMA Royalty Corporation
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Employees
14
Date Price Change Volume
26-07-01 US$42.62 +0.28% 124,640
26-06-30 US$42.50 +0.83% 199,999
26-06-29 US$42.15 0.00% 368,083
26-06-26 US$42.15 -0.12% 439,305
26-06-25 US$42.20 +0.12% 122,047
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
42.62USD
Average target price
39.00USD
Spread / Average Target
-8.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XOMA Stock